# The MEK Inhibitor Trametinib Ameliorates Kidney Fibrosis by Suppressing ERK1/2 and mTORC1 Signaling

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/the-mek-inhibitor-trametinib-ameliorates-kidney-fibrosis-by-suppressing-erk1-2/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Petros Andrikopoulos,Julius Kieswich,Sabrina Pacheco,Luxme Nadarajah,Steven Harwood,Caroline E. O’Riordan,Christoph Thiemermann,Muhammad M. Yaqoob |
| Citations | 76 |
| DOI | 10.1681/asn.2018020209 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://jasn.asnjournals.org/content/jnephrol/30/1/33.full.pdf |
| OpenAlex ID | https://openalex.org/W2903596927 |
| PMID | 30530834 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Julius Kieswich](https://scholariq.org/researchers/julius-kieswich/)

## Paper journal

- [Journal of the American Society of Nephrology](https://scholariq.org/journals/journal-of-the-american-society-of-nephrology/)

## Paper primary topic

- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)

## Paper topics

- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.